Abstract
Since the emergence of regenerative medicine and tissue engineering more than half a century ago, one obstacle has persisted: the in vitro creation of large-scale vascular tissue (>1 cm3) to meet the clinical needs of viable tissue grafts but also for biological research applications. Considerable advancements in biofabrication have been made since Weinberg and Bell, in 1986, created the first blood vessel from collagen, endothelial cells, smooth muscle cells and fibroblasts. The synergistic combination of advances in fabrication methods, availability of cell source, biomaterials formulation and vascular tissue development, promises new strategies for the creation of autologous blood vessels, recapitulating biological functions, structural functions, but also the mechanical functions of a native blood vessel. In this review, the main technological advancements in bio-fabrication are discussed with a particular highlights on 3D bioprinting technologies. The choice of the main biomaterials and cell sources, the use of dynamic maturation systems such as bioreactors and the associated clinical trials will be detailed. The remaining challenges in this complex engineering field will finally be discussed.
Highlights
After many years of research in the field of engineering and regenerative medicine, an obstacle remains: the design and construction of vascularized large-scale in vitro tissues (>1 cm3) for biological studies and transplantation
These layers are composed of endothelial cells (ECs), smooth muscle cells (SMCs) and fibroblasts (FBs), respectively, trapped in a highly organized extracellular matrix (ECM) mainly composed of type I collagen, type III collagen and elastin
Vascular Tissue Engineering an Biofabrication despite advances in pharmacology, material science and device manufacturing, these synthetic tissue-engineering vascular grafts (TEVG) had not significantly reduced overall mortality and morbidity (Nugent and Edelman, 2003). They were exclusively composed of acellular synthetic polymers and, as known today, the natural formation and maintenance of functional blood vessels is an active cell-driven process caused by the growth, death and migration of cells inside biomaterials, as well as by structural changes in tissues through the production and degradation of ECM by the cells themselves (Epstein et al, 1994; McGrath et al, 2005; Touyz, 2005)
Summary
After many years of research in the field of engineering and regenerative medicine, an obstacle remains: the design and construction of vascularized large-scale in vitro tissues (>1 cm3) for biological studies and transplantation. Vascular Tissue Engineering an Biofabrication despite advances in pharmacology, material science and device manufacturing, these synthetic TEVGs had not significantly reduced overall mortality and morbidity (Nugent and Edelman, 2003) They were exclusively composed of acellular synthetic polymers and, as known today, the natural formation and maintenance of functional blood vessels is an active cell-driven process caused by the growth, death and migration of cells inside biomaterials, as well as by structural changes in tissues through the production and degradation of ECM by the cells themselves (Epstein et al, 1994; McGrath et al, 2005; Touyz, 2005). We will present the remaining challenges of vascular tissue engineering as well as the potential solutions and future perspectives in this highly dynamic field of research (Figure 1)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
